Prophylactic use of desmopressin in surgery of six patients with symptomatic heterozygous factor XI deficiency.

3. Talpaz M, Spitzer G, Hittelman W, Kantarjian H, Gutterman J. Changes in granulocyte-monocyte colonyforming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients. Exp Hematol 1986; 14:668-71. 4. Santucci MA, Soligo D, Pileri S, Zuffa E, Testoni N, Tura S. Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leuk Lymphoma 1993; 11(Suppl.1): 113-8. 5. Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fischer RI. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol 1989; 143: 4282-6. 6. Tomás JF, López-Lorenzo JL, Requena MJ, et al. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1998; 22:47-51. 7. Zuffa E, Bandini G, Bonini A, et al. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica 1998; 83:231-6. 8. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85:2981-90. 9. Muñoz A, Bureo E, Ortega JJ, et al. Treatment of Ph1positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON). Haematologica 1998; 83:981-4. 10. Anonymous. Potential clinical implications of early diagnosis of chronic myeloid leukemia. Haematologica 1999; 84:289-90.